Enjoy complimentary customisation on priority with our Enterprise License!
The antithrombotic drugs market is estimated to increase by USD 21.78 billion and grow at a CAGR of 7.68% between 2022 and 2027. The Antithrombotic Drugs Market is experiencing significant growth due to several key factors. These include the rising incidence of coagulation disorders, the emergence of novel oral anticoagulants, and robust research and development activities. However, the market also faces challenges. One significant challenge is the side effects associated with anticoagulant drugs, which can lead to bleeding complications. Another challenge is the widespread availability of generic alternatives, which can limit the market's growth potential. Additionally, there is a prevailing preference for blood clot surgeries over antithrombotic medications in some medical communities, further impacting market size. Despite these challenges, the Antithrombotic Drugs Market is expected to continue growing due to the increasing demand for effective treatments for coagulation disorders.
To learn more about this report, View Report Sample
The market share growth by the oral segment will be significant during the forecast period. The growing popularity of prescription-based drugs, such as oral capsules, is driving the growth of the segment.
Get a glance at the market contribution of various segments View the PDF Sample
The oral segment was valued at USD 21.05 billion in 2018. The growing number of clinical trials and collaborations are further fueling the segment's growth. For instance, in March 2023, Bristol Myers Squibb collaborated with Janssen Pharmaceuticals and announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor FXIa inhibitor for the antithrombotic drug. The drug can treat conditions associated with a thrombotic event and patient bleeding. Anticoagulants, warfarin, clopidogrel, and aspirin are other oral drugs used to treat thrombosis. These factors will drive the growth of the segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The US and Canada are the leading revenue-generating countries in North America due to the increasing prevalence of deep vein thrombosis and pulmonary embolism. Factors such as the increasing awareness of the severity of diseases such as DVT and pulmonary embolism and the advanced healthcare system in the US play a key role in driving the growth of the regional market's growth. This is increasing the growth prospects for the market in the region. The market in North America has many approved therapies, such as warfarin therapy and antiplatelet therapy. Some of these pipeline molecules are expected to be launched during the forecast period. Thus, the market in North America is expected to grow at a significant rate during the forecast period.
Heparins are a pivotal drug class known for their role as antithrombotic agent, impacting blood clotting mechanisms crucial for managing cardiovascular conditions. In recent times, vaccines have garnered attention for their preventive benefits against infectious diseases, contrasting with controversial uses of hydroxychloroquine. These pharmaceutical advancements cater to diverse medical needs, particularly among the geriatric population, where managing cardiovascular risks often involves antiplatelet medications alongside heparins. The synergy between these treatments underscores ongoing research into improving therapeutic outcomes and addressing the complex health needs of aging populations.
The market growth is significantly driven by the increasing prevalence of coagulation disorders. With cardiovascular emergencies and strict lockdown procedures affecting lifestyles, the incidence of conditions like deep vein thrombosis and pulmonary embolism is on the rise. This surge in health issues, particularly among the aging population, underscores the need for antithrombotic drugs to manage thromboembolic and hemorrhagic complications. As cardiovascular diseases and chronic conditions become more prevalent, the demand for antithrombotic medications, such as novel oral anticoagulants and antiplatelet drugs, is expected to escalate. This trend highlights a promising outlook for the market in the forecast period.
The advent of anticoagulant antidotes is a key trend in the market. The preference for oral anticoagulants was low despite the high efficacy of oral anticoagulants in the treatment of thrombosis. This is primarily due to numerous adverse side effects, such as bruising, prolonged nosebleeds, and vomiting blood. The market did not have any antidotes for novel oral anticoagulants, which posed a challenge to the growth of the market.
Antidotes reverse the side effects caused by anticoagulants and help the body regain its ability to clot blood. Pharmaceutical players are researching antidotes for the treatment of thrombosis. The positive results of these antidotes in clinical trials have increased their chances of approval. The pipeline has a few antidotes that are expected to gain approval during the forecast period. Key vendors are expected to launch antidotes, which, in turn, will support market growth during the forecast period.
Strong side effects of anticoagulant drugs will challenge market growth. Anticoagulants or blood thinners are medications developed to dissolve blood clots. However, they have various side effects. They decrease the ability of blood to clot, thereby slowing down the blood clotting process. As a result, the flow of blood becomes uncontrollable.
The long-term use of anticoagulants is associated with cardiovascular risks, such as strokes and heart attacks. Some other side effects associated with using anticoagulants are severe bruising, prolonged nosebleeds, and vomiting blood. The use of anticoagulants is also associated with severe back pain, chest pain, dizziness, headaches, and jaundice. As a result, the use of these drugs is increasing. Therefore, the rising awareness about the side effects of anticoagulants is expected to hinder the growth of the global market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aspen Pharmacare Holdings Ltd - The company offers anti-thrombotic drugs such as Fraxiparine.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
1. Cardiovascular Therapeutics Market: Cardiovascular Therapeutics Market Analysis Asia, North America, Europe, Rest of World (ROW) - US, Mexico, Russia, China, India - Size and Forecast
2. Myocardial Infarction (MI) Therapeutics Market: Myocardial Infarction (MI) Therapeutics Market by Product and Geography - Forecast and Analysis
3. Anticoagulants Market; Anticoagulants Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,UK,Japan - Size and Forecast
Thrombus formation, whether in arterial thrombosis or venous thrombosis, is a critical concern in cardiovascular disorders and other chronic diseases. Management often involves thrombolytic drugs like thrombolytic agents and direct thrombin inhibitors, which target clot dissolution. Vitamin K antagonists and antiplatelet agents are crucial in preventing clot formation, while glycoproteins play roles in clotting processes. Research into these medications addresses diverse health conditions such as obesity, diabetes, hypertension, cancer, and stroke, which are linked to increased cardiovascular events. Government measures and reimbursement policies influence access to these treatments amid rising healthcare costs exacerbated by sedentary lifestyles. The oral route of administration for these drugs enhances patient compliance and management of thrombotic risks associated with various genetic disorders and heart-related ailments. Medication research focuses on developing effective therapies for managing thrombotic events, cardiovascular problems, and heart-related ailments, including antiplatelet medicine and thrombolytic medications for cardiovascular diseases (CVDs).
Industry Scope |
|
Report Coverage |
Details |
Page number |
161 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.68% |
Market growth 2024-2028 |
USD 21.78 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.32 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key countries |
US, Germany, UK, Japan, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market forecasting growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.